

Acute Kidney Injury Prevention

Preoperative

- Perform a kidney health assessment, to include medical and medication history, baseline kidney function, previous episodes of AKI, nephrotoxin exposure, assessment of anemia.
- Perform a complete urinalysis: consult nephrology for proteinuria
- Optimize glycemic control by maintaining blood glucose <180 mg/dL
- Hold ACE inhibitors and ARBs for 48 hours preoperatively
- Limit aminoglycoside antibiotics unless there is a history of anaphylaxis to penicillin or cephalosporins, or infectious indication. The nephrotoxicity of the glycopeptide antibiotic vancomycin is controversial, and it should be used judiciously.
- Give clear liquids until 2 hours before general anesthesia to reduce the risk of dehydration

Intraoperative

- Optimize glycemic control by maintaining blood glucose <180 mg/dL with an insulin infusion
- Limit aminoglycoside antibiotics
- Perform goal-directed perfusion targeting global oxygen delivery (DO₂) > 270 ml/min/m²
- Avoid >37° C on rewarming from cardiopulmonary bypass


Postoperative (first 24-48 hours)

- Optimize glycemic control by maintaining blood glucose >80 and <180 mg/dL with an insulin infusion
- Hold ACE inhibitors and ARBs in oliguric/high AKI risk patients
- Limit aminoglycoside antibiotics
- Avoid NSAIDs
- Avoid intravenous radio-contrast agents if possible
- Monitor sCr daily and UO hourly until there are no further indicators of CSA-AKI, call for oliguria (UO <0.5 cc/kg/hr using lean body mass)
- Utilize continuous invasive or noninvasive functional hemodynamic hourly monitoring to maintain optimal intravascular blood volume:
 - Fluid challenges with lactated ringers for responsiveness if oliguric, cardiac index < 2.0 L/min/m² and CVP <5 mmHg, PAD <14 mmHg
 - Diuretics for CVP >15 mmHg or PAD > 20 mmHg. Consider ultrafiltration if diuretic unresponsive.
- Implement goal-directed hemodynamic therapy in oliguric/high AKI risk/positive biomarker patients (Nephrocheck >0.7): Utilizing fluids, diuretics, and inotropes to maintain:
 - o SBP 100 130 mmHg or MAP 65 90 mmHg
 - Cardiac Index >2.2 L/min/m²
 - o UO >0.5 ml/kg/hr
 - SVO2 > 55% (optimize Hg, PaO₂, and Cardiac Index)
- Limit transfusion of PRBC to a Hgb < 7.0 and evidence of oliguria, lactic acidosis, low cardiac output or positive urinary biomarkers
- For persistent oliguria (UO < .5 cc/kg/hr for 3 hours) or SCr rise > 0.3 mg/dL:
 - o Verify the patency of the urinary catheter
 - Adjust medication dosing/interval for renal function per institutional policies or discontinue nephrotoxic medications (e.g., gentamycin, enoxaparin, etc.)

Legend: Orders in Bold are based on Class I or IIA recommendations,

Orders in italics were inconsistently Class I or IIA, or Class IIB/supported by evidence published in peer-reviewed journals.

Abbreviations-DAPT-dual antiplatelet Therapy, DOAC-direct-acting oral anticoagulants, Hgb-hemoglobin, IV-intravenous, CPB-cardiopulmonary bypass, ACT-activated clotting time, PT-prothrombin time, PTT-partial thromboplastin time, FFP-fresh frozen plasma, PRBC-packed red blood cells, DDAVP- deamino-8-D-arginine vasopressin



Strong and Moderate Recommendations	STS/SCA/AmSECT Guidelines ²	ADQI Consensus ³	ERAS Cardiac Guidelines ⁴	POQI/ERAS Consensus
	duidelines	ADQI Collsellsus	Guidelines	Consensus
Preoperative Perform a kidney health assessment				∠
Consume clear liquids up until 2-4 hours before			<i>\rightarrow</i>	
general anesthesia				
Discontinue ACE inhibitors and ARBs	▶	∠		~
Optimize preoperative glycemic control by maintaining blood glucose <180 mg/dL		~	~	
Intraoperative				
Preserve adequate intravascular volume in the setting of dynamic fluid shifts and cardiopulmonary compromise				~
Restrict the use of excessive ultrafiltration and hemoconcentration during cardiopulmonary bypass		~		~
Use individualized, perioperative goal-directed therapy to reduce the incidence of CSA-AKI				~
Avoid hyperthermic perfusion (>37 °C) on cardiopulmonary bypass	~		~	
Use a goal-directed oxygen delivery strategy on cardiopulmonary bypass.	~			<i>~</i>
Optimize intraoperative glycemic control by maintaining blood glucose 80-180 mg/dL	~	~	~	~
Use intraoperative blood salvage to maintain hematocrit above a prescribed threshold				<i>\(\righta\)</i>
Postoperative				
Avoid prophylactic or otherwise routine use of diuretic therapy		~		"
Refer new KDIGO stage 2 or 3 CSA-AKI for long- term follow-up				~
Perform a multidisciplinary review of all new, persistent, dialysis-dependent CSA-AKI				~
Implement a KDIGO bundle of care ^b for patients at high risk for AKI	~	~	∠	<i>\\</i>
Optimize postoperative glycemic control by maintaining blood glucose 80-180 mg/dL	~	~	~	~
Use a low tidal volume ventilation strategy (<10 mL/kg)		~	~	

² Brown JR, Baker RA, Shore-Lesserson L, et al. The Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American Society of Extracorporeal Technology Clinical Practice Guidelines for the Prevention of Adult Cardiac Surgery–Associated Acute Kidney Injury. Ann Thorac Surg. 2023;115:34-42.

³ Nadim MK, Forni LG, Bihorac A, et al. Cardiac and vascular surgery- associated acute kidney injury: the 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group. J Am Heart Assoc. 2018;7:e008834.

⁴ Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for perioperative care in cardiac surgery: Enhanced Recovery After Surgery Society recommendations. JAMA Surg. 2019;154:755-766.

^a Brown J, Shaw AD, Mythen MG, et al. Adult Cardiac Surgery Associated Acute Kidney Injury: Joint Consensus Report of the PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS®) Cardiac Society. Submitted to J Cardiothorac Vasc Anesth.